Highlights From the 2026 ASCO GI Cancers...

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I' ... Show More

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I ... Show More

<p><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer.</span></p> <p><span style= ... Show More

Dr. Sepideh Gholami and Dr. Aaron Scott join us to discuss the latest evidence-based guideline from ASCO on the management of locally advanced rectal cancer. They review the recommendation highlights on topics including assessment, total neoadjuvant therapy, timing of chemotherap ... Show More

Dr. Rohan Garje shares the updated recommendations for the ASCO guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer. He discusses the systemic therapy options for patients based on prior therapy received in the castration-sensitive and ... Show More

Bias in the way medical research is carried out means that new medicines for diseases such as cancer – as well as the tools used to diagnose patients with some conditions – are disproportionally tested on people of European heritage. This can lead to those not represented in the ... Show More

Breast cancer is the most common cancer among women globally. And yet, many people pass up opportunities to get screened for the disease, often because of the invasive and sometimes painful process of mammograms. Chemist and professor Simona Francese presents a potentially ground ... Show More

"Cancer doesn't have to be a death sentence. It can be an awakening to a whole new way of living." - Dr. Nasha Winters Today, I sit down with Dr. Nasha Winters for an eye-opening conversation about revolutionizing cancer care. From her own journey surviving stage 4 ovarian cance ... Show More

In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington U ... Show More

Our guest is Dr. Kyle Richards, a urologic oncologist and Associate Professor in the Department of Urology at the University of Wisconsin. He talks with us about the basics around non-muscle invasive bladder cancer. Learn about common symptoms, diagnosis and treatment options to ... Show More

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ... Show More

When someone finishes a cancer treatment, it can feel like the end of the story. For many, it may just be the beginning–risk of recurrence looms, long-term medications (and their side effects) begin, and it’s hard to get your bearings. What do you really need to know?In this cand ... Show More

<p class="" style="white-space:pre-wrap;">Lung cancer is one of the most commonly diagnosed type of cancer and so it is fitting that we start the first of our disease-specific oncology series with this diagnosis. An important component of treatment in lung cancer (and many other ... Show More